Imaging predictors of treatment outcomes in rectal cancer: an overview
The treatment protocols for rectal cancer continue to evolve, with increasing acceptance of a watch-and-wait policy for clinical complete responders to neoadjuvant chemoradiation therapy. It still, however, remains unclear who is likely to achieve a pathological complete response, which unequivocally portends a very favorable overall prognosis. Evolution of modern imaging techniques has paved the way for potential prediction of treatment response based on baseline, on-treatment, early post-treatment and subsequent follow-up imaging alone. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 20, 2018 Category: Cancer & Oncology Authors: Lakshmi Shree Mahadevan, James Zhong, BhanuPrasad Venkatesulu, Harmeet Kaur, Shreerang Bhide, Bruce Minsky, William Chu, Martijn Intven, Uulke A. van der Heide, Baukelien van Triest, Sunil Krishnan, William Hall Source Type: research

Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review
Colorectal cancer (CRC) is second most commonly diagnosed cancer in women and third in men and is responsible for almost 0.7 million deaths annually worldwide. (Torre et al., 2015) Recent data suggests a shift in incidence with a decreasing trend in patients over 50, and an increasing trend in those below 50. (Davis et al., 2011; Siegel et al., 2017) Early detection of CRC is associated with 5-year survival rates as high as 93% in patients staged T1/2N0M0. However, over 20% of patients present with metastatic disease at diagnosis, and up to half surgically radically treated patients will develop metastases. (Source: Critic...
Source: Critical Reviews in Oncology Hematology - June 19, 2018 Category: Cancer & Oncology Authors: J. Kobiela, P. Spychalski, G. Marvaso, D. Ciardo, V. Dell ’Acqua, F. Kraja, A. Błażyńska-Spychalska, A.J. Łachiński, A. Surgo, R. Glynne-Jones, B.A. Jereczek-Fossa Source Type: research

A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia
Anemia is a condition characterized by a deficiency of red blood cells (RBCs) or hemoglobin (Hb), resulting in a diminished capacity of the blood to carry and deliver oxygen to tissues and organs (Abbasi et al., 2014). Anemia is often multifactorial in etiology and may be patient- (e.g., iron-deficiencies, vitamin deficiencies), disease- (e.g., bone marrow diseases, chronic diseases, hemorrhage), or anticancer treatment- (e.g., chemotherapy, radiotherapy, precision therapies) related (Crathorne et al., 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 19, 2018 Category: Cancer & Oncology Authors: Luiz H. Arantes, Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, Jay Wish Source Type: research

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology
Developing nanoparticles to improve the specificity of anticancer agents towards tumor tissue and to better control drug delivery is a rising strategy in oncology. An increasing number of forms (e.g., conjugated nanoparticles, liposomes, immunoliposomes …) are now available on the shelves and numerous other scaffolds (e.g., dendrimeres, nanospheres, squalenes …) are currently at various stages of development. However, as of today most nanoparticles made available remain lipidic carriers. Pharmacokinetic variability is a major, yet largely under estimated issue with liposomal nanoparticles. (Source: Critical R...
Source: Critical Reviews in Oncology Hematology - June 19, 2018 Category: Cancer & Oncology Authors: Anne Rodallec, Sebastien Benzekri, Bruno Lacarelle, Joseph Ciccolini, Raphaelle Fanciullino Source Type: research

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
Since early 90  s platinum-based chemotherapy has been the mainstay of treatment for metastatic Non Small Cell Lung Cancer (NSCLC) (Non-small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002). However, during the last two decades front line treatment of metastatic NSCLC has profoundly changed mo ving from the old “one size fits all” concept to a “histology-based” approach and then, for a small subgroup of patients (i.e. EGFR mutated and ALK-rearranged NSCLCs), to a “molecularly-selected” one (Russo et al., 2015). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 15, 2018 Category: Cancer & Oncology Authors: A Russo, T Franchina, GRR Ricciardi, G Toscano, S Schifano, G Lo Certo, A Battaglia, E Pant ò, M Scaffidi Fonti, V Adamo Source Type: research

Immune check-point in cervical cancer
Cervical cancer (CC) is still one of the most commonly diagnosed cancer and one of the mainly leading cause of cancer death in female population (Siegel et al., 2017). Surgery, radiation therapy, chemotherapy or a combination of these therapeutic modalities represent the classical options to CC management (Anon, 2018; Marchetti et al., 2017). The appropriate strategy is based on tumor stage at diagnosis, but it remains dismal to improve survival in locally advanced or recurrent/metastatic disease (Pfaendler and Tewari, 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 15, 2018 Category: Cancer & Oncology Authors: F. De Felice, C. Marchetti, I. Palaia, R. Ostuni, L. Muzii, V. Tombolini, P. Benedetti Panici Source Type: research

Antiangiogenic therapy: markers of response, “normalization” and resistance
Currently in cancer treatment, one premise is to use antiangiogenic therapies in association with chemotherapy or radiotherapy to augment their efficacy by benefiting from the vascular “normalization” induced by antiangiogenic therapy. This concept defines the time during which the tumor blood vessels adopt normal-like morphology and functionality, i.e. the blood vessels become more mature, the perfusion augments and hypoxia decreases. To date, there is such a diversity of tre atment protocols where the type of antiangiogenic to adopt, its dose and duration of administration are different, that knowing when and...
Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Karima El Alaoui-Lasmaili, B éatrice Faivre Source Type: research

Radiation therapy in renal cell carcinoma
Traditionally, renal cell carcinoma (RCC) has been considered a radioresistant tumor and therefore radiation therapy (RT) was mainly confined in treatment of metastasis. New advances in RT techniques, including stereotactic irradiation, have made encouraging contributions in the oncologic scenario, opening up new opportunities in RCC management. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Francesca De Felice, Vincenzo Tombolini Source Type: research

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Eribulin mesylate (hereafter referred to as “eribulin”), a synthetic analog of halichondrin B, is a microtubule-targeting chemotherapeutic agent (Mani and Swami, 2010; Swami et al., 2012). It can inhibit mitotic spindle formation by targeting the growth phase of microtubules, which results in increased apoptosis and decreased cell prolife ration (Jordan et al., 2005). This new mechanism of action is distinct from those traditional tubulin-targeting agents such as taxanes, paclitaxel and vinblastine (Dybdal-Hargreaves et al., 2015). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Bin Zhao, Hong Zhao, Jiaxin Zhao Source Type: research

Bone Marrow Versus Peripheral Blood as a Graft Source for Haploidentical Donor Transplantation in Adults Using Post-Transplant Cyclophosphamide —A Systematic Review and Meta-Analysis
Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT, particularly for patients using post-transplant cyclophosphamide (PTCy), which is the standard therapy. However, to date, no meta-analysis focusing on this issue has been published. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 11, 2018 Category: Cancer & Oncology Authors: Xiaotong Yu, Liping Liu, Zhenwei Xie, Chongya Dong, Libo Zhao, Jingru Zhang, Hong-Hu Zhu, Jian Gu Source Type: research

Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma
Pimozide is currently being used in clinic as a neuroleptic and exerts versatile biological actions. Pimozide is a cationic amphiphilic drug (CAD); CADs block the synthesis of neutral lipids, impair cholesterol homeostasis of cancer cells and increase accumulation of diacylglycerol-3-phosphate. Pimozide exerts tumoricidal activity which was first shown for melanoma and neuroblastoma via proposed anti- dopaminergic effects. Recently, pancreas cancers are shown to elevate dopamine receptor-2 synthesis, which is blocked by pimozide leading growth inhibition. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 11, 2018 Category: Cancer & Oncology Authors: Ilhan Elmaci, Meric A. Altinoz Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 9, 2018 Category: Cancer & Oncology Source Type: research

Tafro syndrome: critical review for clinicians and pathologists
TAFRO is an acrostic and includes thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R) and organomegaly (O) (Takai et al., 2013). TAFRO syndrome has been described firstly by Takai in Japanese patients. However TAFRO cases have been reported from US, Europe and other countries (Takai et al., 2010; Iwaki et al., 2016; Abdo et al., 2014). Three major and at least one minor criteria and exclusion of infectious, rheumatologic and neoplastic diseases are required for the diagnosis of TAFRO. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 6, 2018 Category: Cancer & Oncology Authors: Paydas Semra Source Type: research

Anthropometric factors and non-Hodgkin ’s lymphoma risk: Systematic review and meta-analysis of prospective studies
The associations between anthropometric factors and non-Hodgkin ’s lymphoma (NHL) risk remain inconclusive. A meta-analysis was performed to clarify these associations. PubMed and Web of Science were searched for relevant prospective observational studies. A random-effects model was used to generate the summary relative risks (RRs) with 95% confidence interval s (CIs). A total of 22 prospective cohort studies, with over 20,000 NHL cases, were included in the present meta-analysis. The summary RRs of NHL risk were 1.06 (95% CI 1.03, 1.09) for each 5 kg/m2 increase in body mass index (BMI), 1.11 (95% CI 1.07, 1.16) f...
Source: Critical Reviews in Oncology Hematology - June 6, 2018 Category: Cancer & Oncology Authors: Khemayanto Hidayat, Hui-Juan Li, Bi-Min Shi Source Type: research

A revisited concept. Tumors: Wounds that do not heal
In 1986, Harold F. Dvorak, Professor of Pathology at Harvard Medical School Boston, published an essay in the New England Journal of Medicine entitled “Tumors: Wounds that do not heal” pointed out that similarities exist between tumor stroma generation and wound healing. Cancers share many features in common with tissue regeneration, including immune response, cell proliferation, cell migration, tissue remodeling, and cell death. In this revie w article, I analyzed the importance and the limits of this important concept, which confirm the close relationship between apparently different biological processes. (So...
Source: Critical Reviews in Oncology Hematology - June 6, 2018 Category: Cancer & Oncology Authors: Domenico Ribatti, Roberto Tamma Source Type: research

Molecular targets of celastrol in cancer: Recent trends and advancements
In the past few decades, the interest in medicinal plants and their bioactive molecules has extensively grown, and many of such agents exhibit diverse effects on suppressing the development and progression of neoplasms, both in vitro as well in vivo animal models (Kashyap et al., 2016d; Kumar et al., 2016; Tuli et al., 2014). It is widely believed that such substances can provide a plausible alternative to synthetic drugs due to their potency, safety, and lower cost (Hansen et al., 2011). One of such potential natural agent is celastrol, a quinine methide triterpenoid. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 5, 2018 Category: Cancer & Oncology Authors: Dharambir Kashyap, Ajay Sharma, Hardeep Singh Tuli, Katrin Sak, Tapan Mukherjee, Anupam Bishayee Source Type: research

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): towards a less dismal future?
The onset of Brain Metastases (BM) is proportionally greater in lung cancer than in other solid tumors (Barnholtz-Sloan et al., 2004), with significant impact on patients performance status (PS) and prognosis (Ali and Goffin, 2013). Synchronous or metachronous central nervous system (CNS) spread occurs in about 20% and 40% of Non-Small Cell Lung Cancer (NSCLC) cases, respectively (Langer and Mehta, 2005; S ørensen et al., 1988). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 24, 2018 Category: Cancer & Oncology Authors: Frega Stefano, Bonanno Laura, Guarneri Valentina, Conte Pier Franco, Pasello Giulia Source Type: research

Manipulating macrophage polarization and function using classical HDAC inhibitors: implications for autoimmunity and inflammation
Macrophages are important player in defense against invading pathogens and their dysfunction is linked to most of inflammatory and autoimmune diseases. Inflammation is a normal and physiological response of the immune system against harmful stimuli such as infection and injury. However, when allowed to continue unchecked, under certain conditions it turns into autoimmune or inflammatory diseases, neurodegeneration, and carcinogenesis. Currently, several safe and effective anti-inflammatory drugs are available with many more drugs in the development pipeline, among which are histone deacetylase inhibitors. (Source: Critical...
Source: Critical Reviews in Oncology Hematology - May 23, 2018 Category: Cancer & Oncology Authors: Asadollah Mohammadi, Atefeh Sharifi, Reza Pourpaknia, Saeed Mohammadian, Amirhossein Sahebkar Source Type: research

Perioperative Chemotherapy for Urothelial Carcinoma of the Upper Urinary Tract: A Systematic Review and Meta-Anaysis
Upper tract urothelial carcinomas are rare malignancies with differences in anatomy and biology requiring therapeutic strategies that differ from bladder cancer. The role of perioperative systemic therapy in this disease remains uncertain with limited data to support its use. A systematic review of the literature and meta-analysis was therefore undertaken to provide more information and guide clinical practice (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 21, 2018 Category: Cancer & Oncology Authors: Richard W. Gregg, Francisco E. Vera-Badillo, Christopher M. Booth, Aamer Mahmud, Michael Brundage, Michael J. Leveridge, Timothy P. Hanna Source Type: research

Glutathione system in animal model of solid tumors: From regulation to therapeutic target
Glutathione (GSH) is involved in scavenging reactive oxygen species (ROS) to maintain antioxidant defenses and regulate redox-dependent cell signaling (Masella et al., 2005). GSH is also involved in several metabolic processes, including the synthesis of proteins and DNA, enzyme activity, metabolism, gene expression, signal transduction, and the intensification of cytoplasmic and transmembrane transport (Meister and Anderson, 1983; Zmorzy ński et al., 2015). The detoxification of xenobiotics and endogenous compounds is another relevant function of GSH (Ballatori et al., 2009). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 21, 2018 Category: Cancer & Oncology Authors: Claudia Rita Corso, Alexandra Acco Source Type: research

Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers
Gynecologic cancer is any cancer that starts in a woman ’s reproductive organs such as ovary, uterine, vagina and vulva (Coukos et al., 2016). Each gynecologic cancer is unique, with different clinical symptoms, risk factors, prevention strategies and treatments (Alkatout et al., 2015; Colombo and Peiretti, 2010; Yang et al., 2016). Multiple treatment modalities for gynecologic cancers include surgery, chemotherapy, and radiation, depending on the kind of cancer and how far it has spread (Cortez et al., 2017; Ventriglia et al., 2017; van Poelgeest et al., 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 18, 2018 Category: Cancer & Oncology Authors: Chiara Di Tucci, Michele Carlo Schiavi, Pierangelo Faiano, Ottavia D ’Oria, Giovanni Prata, Valentina Sciuga, Andrea Giannini, Innocenza Palaia, Ludovico Muzii, Pierluigi Benedetti Panici Source Type: research

A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival
Due to its fatal consequences, esophageal cancer is one of the most severe types of cancers (Umar and Fleischer, 2008). With more than 450,000 new cases and 400,000 deaths, it is the eighth most common cancer and the sixth leading cause of death from cancer in the world (Ferlay et al., 2010; Pennathur et al., 2013). Because of its aggressive nature, the prognosis of the disease is poor. Despite improvements in treatment interventions, the five-year survival of the disease is approximately 20 percent (Ferlay et al., 2010; Mao et al., 2011; Shibata et al., 2011). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Amin Doosti-Irani, Kourosh Holakouie-Naieni, Abbas Rahimi-Foroushani, Mohammad Ali Mansournia, Peiman Haddad Source Type: research

Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities
Primary central nervous system lymphoma (PCNSL) occurs within the special sanctuary of the blood-brain barrier and is therefore regarded as an ‘immune-privileged (IP)’ lymphoma. The majority of PCNSLs are diffuse large B-cell lymphomas (DLBCLs) (Louis et al., 2007; Bhagavathi and Wilson, 2008), which originate from late germinal centre (GC) B-cells (Deckert et al., 2014; Courts et al., 2008; Coupland and Damato, 2008; Alizadeh et al., 2000) or early post-GC B-cells with blocked terminal differentiation (Camilleri-Broet et al., 2006; Braggio et al., 2015; Montesinos-Rongen et al., 2004; Coupland and Damato, 2008...
Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Laura S. Hiemcke-Jiwa, Roos J. Leguit, Tom J. Snijders, N. Mehdi Jiwa, Jonas. J.W. Kuiper, Roel A. de Weger, Monique C. Minnema, Manon M.H. Huibers Source Type: research

5-Lipoxygenase: its involvement in gastrointestinal malignancies
Chronic inflammation is increasingly known as one of the most critical etiological factors in gastrointestinal (GI) cancers (Lee et al., 2016; Wang and Cho, 2015). Overexpression of 5-lipoxygenase (5-LOX), 5-LOX-activating protein (FLAP), as well as other leukotriene (LT) biosynthetic enzymes have been reported in many malignant cells of the GI tract including the colon, rectum, esophagus, and pancreas (Chen et al., 2004; Li et al., 2005; Melstrom et al., 2008; Wasilewicz et al., 2010). There are several pieces of evidence suggesting that 5-LOX triggers the progression and initiation of GI malignancies (Moore and Pidgeon, ...
Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Neha Merchant, Lakkakula Venkata Kameswara Subrahmanya Bhaskar, Saimila Momin, Peela Sujatha, Aramati B.M. Reddy, Ganji Purnachandra Nagaraju Source Type: research

Cancer Cachexia: Diagnosis, Assessment, and Treatment
Cachexia is a multifactorial and multi-organ syndrome that is one of the main causes of morbidity and mortality in late stages of chronic conditions such as AIDS, chronic obstructive pulmonary disease (COPD), congestive heart failure, multiple sclerosis, tuberculosis, and cancer. More than 50 percent of cancer patients suffer from cachexia at death, with the distribution varying by tumor type; the incidence is highest in patients with gastric and pancreatic cancer ( ∼80%) while patients with breast cancer and leukemia demonstrate the lowest frequency (∼40%) of affliction with cachexia (Argiles et al., 2005; Muscari...
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Mohammadamin Sadeghi, Mahsa Keshavarz-Fathi, Vickie Baracos, Jann Arends, Maryam Mahmoudi, Nima Rezaei Source Type: research

Surgical treatment of pulmonary metastasis in colorectal cancer patients: Current practice and results
Colorectal cancer (CRC) is one of the four major cancer sites, along with breast, lung and prostate (Siegel et al., 2013; Siegel et al., 2014a). It is estimated that approximately 1  in.20 people will develop CRC over their lifetime, although this number may be decreasing, indicating progress in CRC detection or prevention (Siegel et al., 2017; Siegel et al., 2014b). Approximately 65% of all patients developing CRC will survive 5 years after the diagnosis (Siegel et al., 2013 ; Siegel et al., 2014b), but this figure varies widely with the CRC stage at detection (Siegel et al., 2013; Siegel et al., 2014a). (Source: Critic...
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Matthieu Zellweger, Etienne Abdelnour-Berchtold, Thorsten Krueger, Hans-Beat Ris, Jean Yannis Perentes, Michel Gonzalez Source Type: research

The Unfolded Protein Response as a Target for Anticancer Therapeutics
The endoplasmic reticulum (ER) is an essential organelle in eukaryotic cells, responsible for protein synthesis, folding, sorting, and transportation. ER stress is initiated when the unfolded or misfolded protein load exceeds the capacity of the ER to properly fold protein. Tumor microenvironmental conditions, such as nutrient deprivation, hypoxia, and oxidative stress perturb protein folding and trigger chronic ER stress. Cancer cells can tolerate mild ER stress, however, persistent and severe ER stress kills cancer cells by inducing their autophagy, apoptosis, necroptosis, or immunogenic cell death. (Source: Critical Rev...
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Mengxiong Wang, Mary E. Law, Ronald K. Castellano, Brian K. Law Source Type: research

Antinuclear antibodies and cancer: A literature review
Antinuclear antibodies (ANAs) are a spectrum of autoantibodies that react with various nuclear and cytoplasmic components of normal human cells. The development of autoantibodies is the consequence of breakdown of immunologic tolerance, but their presence is not exclusive of autoimmune conditions. They are very important serological markers for different autoimmune disease, like connective tissue diseases (CTD) —eg, systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), scleroderma (SSc), polymyositis (PM), or mixed connective tissue disease (MCTD). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Alexandru Vlagea, Sandra Falagan, Gerardo Guti érrez-Gutiérrez, Juan Moreno-Rubio, María Merino, Francisco Zambrana Tébar, Enrique Casado, María Sereno Source Type: research

A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
A considerable number of breast and ovarian carcinomas are due to underlying BRCA gene aberrations. Of these, BRCA germline mutations and BRCA promoter methylation are thought to be mutually exclusive, which could be exploited in clinical practice. However, this paradigm has not been studied extensively and systematically. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 14, 2018 Category: Cancer & Oncology Authors: Shoko Vos, Paul Joannes van Diest, Cathy Beatrice Moelans Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 12, 2018 Category: Cancer & Oncology Source Type: research

The Clinical Significance of Platelet-Derived Growth Factors (PDGFs) and their Receptors (PDGFRs) in Gastric Cancer: A Systematic Review and Meta-Analysis
This study sought to employ meta-analysis to evaluate PDGFs/PDGFRs status prognostic significance and their association with clinicopathological features of gastric cancer. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 11, 2018 Category: Cancer & Oncology Authors: Hai Qian, Kwaku Appiah-Kubi, Ying Wang, Min Wu, Yan Tao, Yan Wu, Yongchang Chen Source Type: research

Corrigendum to “Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review” [Crit. Rev. Oncol./Hematol. 124, April (2018), 61–65]
The authors regret that the authors name Jean-Louis Frossard was incorrectly spelt when the article was published. This is now correct in the article. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 4, 2018 Category: Cancer & Oncology Authors: Tsz Yeung Kam, Melpomeni Kountouri, Arnaud Roth, Jean-Louis Frossard, Olivier Huber, Stefan M önig, Thomas Zilli Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 27, 2018 Category: Cancer & Oncology Source Type: research

Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis
The objective of the present systematic review and meta-analysis was to evaluate possible alterations in serum PON1 activity in patients with cancer. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 26, 2018 Category: Cancer & Oncology Authors: M. Arenas, E. Rodr íguez, A. Sahebkar, S. Sabater, D. Rizo, O. Pallisé, M. Hernández, F. Riu, J. Camps, J. Joven Source Type: research

“No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!
For decades, standard cytotoxics have been good examples highlighting efficacy-toxicity relationships. More recently, evidences were brought by Sehouli and coworkers (Sehouli et al., 2015) analyzing retrospectively 4 controlled phase-III trials in 5114 advanced ovarian cancer patients treated with platinum and taxanes. They found that patients with grade-2 alopecia over their three first cycles exhibited significantly longer overall survival compared to patients who underwent delayed alopecia. However, the authors failed to show a clear direct link between severity of alopecia and survival, leaving open the question of an ...
Source: Critical Reviews in Oncology Hematology - April 17, 2018 Category: Cancer & Oncology Authors: G. Milano, F. Innocenti, B. Lacarelle, J. Ciccolini Source Type: research

The influence of genetic variation on late toxicities in childhood cancer survivors: A review
The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 12, 2018 Category: Cancer & Oncology Authors: E. Clemens, A.L.F. van der Kooi, L. Broer, E. van Dulmen-den Broeder, H. Visscher, L. Kremer, W. Tissing, J. Loonen, C.M. Ronckers, S.M.F. Pluijm, S.J.C.M.M. Neggers, O. Zolk, T. Langer, A. am Zehnhoff-Dinnesen, C.L. Wilson, M.M. Hudson, B. Carleton, J.S. Source Type: research

The influence of genetic variation on late toxicities in childhood cancer survivors: a review
The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 12, 2018 Category: Cancer & Oncology Authors: E. Clemens, A.L.F. van der Kooi, L. Broer, E. van Dulmen-den Broeder, H. Visscher, L. Kremer, W. Tissing, J. Loonen, C.M. Ronckers, S.M.F. Pluijm, S.J.C.M.M. Neggers, O. Zolk, T. Langer, A. am Zehnhoff-Dinnesen, C.L. Wilson, M.M. Hudson, B. Carleton, J.S. Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 10, 2018 Category: Cancer & Oncology Source Type: research

Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia
Acute lymphoblastic leukaemia (ALL) is a prevalent form of pediatric cancer that accounts for 70 –80% of all leukemias. Genome-based analysis, exome sequencing, transcriptomics and proteomics have provided insight into genetic classification of ALL and helped identify novel subtypes of the disease. B and T cell-based ALL are two well-characterized genomic subtypes, significantly marked by bon e marrow disorders, along with mutations in trisomy 21 and T53. The other ALLs include Early T-cell precursor ALL, Philadelphia chromosome-like ALL, Down syndrome-associated ALL and Relapsed ALL. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 10, 2018 Category: Cancer & Oncology Authors: Chuan Wu, Wei Li Source Type: research

Genomics and pharmacogenomics of Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukaemia (ALL) is a prevalent form of pediatric cancer that accounts for 70-80% of all leukemias. Genome-based analysis, exome sequencing, transcriptomics and proteomics have provided insight into genetic classification of ALL and helped identify novel subtypes of the disease. B and T cell-based ALL are two well-characterized genomic subtypes, significantly marked by bone marrow disorders, along with mutations in trisomy 21 and T53. The other ALLs include Early T-cell precursor ALL, Philadelphia chromosome-like ALL, Down syndrome-associated ALL and Relapsed ALL. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 10, 2018 Category: Cancer & Oncology Authors: Chuan Wu, Wei Li Source Type: research

Organization, quality and cost of oncological home-hospitalization: A systematic review
Worldwide, cancer is a major threat to public health. The social as well as economic consequences remain significant for patients and societies (Luengo-Fernandez et al., 2013; Costa et al., 2016; Markman and Luce, 2010). The World Economic Forum estimated direct costs of cancer treatment and attended costs of income losses at US$ 290 billion in 2010 (Bloom et al., 2011). Within the European Union, total cancer costs were estimated at €126 billion in 2009, whereof €51 billion accounted for healthcare (Luengo-Fernandez et al., 2013). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 9, 2018 Category: Cancer & Oncology Authors: Lieselot Cool, Dominique Vandijck, Philip Debruyne, Melissa Desmedt, Tessa Lefebvre, Michelle Lycke, Pieter Jan De Jonghe, Hans Pottel, Veerle Foulon, Koen Van Eygen Tags: Review Source Type: research

The emerging co-regulatory role of long noncoding RNAs in epithelial-mesenchymal transition and the Warburg effect in aggressive tumors
In the last several decades, cancer researchers have reported many distinct hallmarks of tumor cells (Hanahan and Weinberg, 2011). Among the mechanisms that lead to these phenotypes, epithelial-to-mesenchymal transition (EMT) is emerging as a central driver of several malignant behaviors (Kalluri and Weinberg, 2009). EMT is well defined as a series of events in which epithelial cells lose their epithelial characteristics, intercellular contacts and cellular polarity, and acquire various features of mesenchymal cells, such as increased motility, invasiveness, and resistance to apoptosis (Thiery et al., 2009). (Source: Criti...
Source: Critical Reviews in Oncology Hematology - April 9, 2018 Category: Cancer & Oncology Authors: Qian Hua, Baoming Mi, Gang Huang Source Type: research

Organization, Quality and Cost of Oncological Home-Hospitalization: A Systematic Review
Worldwide, cancer is a major threat to public health. The social as well as economic consequences remain significant for patients and societies [1 –3]. The World Economic Forum estimated direct costs of cancer treatment and attended costs of income losses at US$ 290 billion in 2010 [4]. Within the European Union, total cancer costs were estimated at €126 billion in 2009, whereof €51 billion accounted for healthcare [1]. Given the increas ing incidence and prevalence as well as the advanced screening and treatment modalities, there is no doubt cancer costs will only expand [4–7]. (Source: Critical Revi...
Source: Critical Reviews in Oncology Hematology - April 9, 2018 Category: Cancer & Oncology Authors: Lieselot Cool, Dominique Vandijck, Philip Debruyne, Melissa Desmedt, Tessa Lefebvre, Michelle Lycke, Pieter Jan De Jonghe, Hans Pottel, Veerle Foulon, Koen Van Eygen Source Type: research

The emerging co-regulatory role of long noncoding RNAs in epithelial-mesenchymal transition and the Warburg effect in aggressive tumors
In the last several decades, cancer researchers have reported many distinct hallmarks of tumor cells (Hanahan and Weinberg, 2011). Among the mechanisms that lead to these phenotypes, epithelial-to-mesenchymal transition (EMT) is emerging as a central driver of several malignant behaviors (Kalluri and Weinberg, 2009). EMT is well defined as a series of events in which epithelial cells lose their epithelial characteristics, intercellular contacts and cellular polarity, and acquire various features of mesenchymal cells, such as increased motility, invasiveness, and resistance to apoptosis (Thiery et al., 2009). (Source: Criti...
Source: Critical Reviews in Oncology Hematology - April 9, 2018 Category: Cancer & Oncology Authors: Qian Hua, Baoming Mi, Gang Huang Source Type: research

The role of heme iron molecules derived from red and processed meat in the pathogenesis of colorectal carcinoma
Meat a versatile food, is a source of high quality proteins, essential amino acids and many micronutrients including iron, selenium, zinc, vitamin B6, vitamin B12 and omega-3- polyunsaturated fatty acids (Celada et al., 2016). Red meat is defined as flesh from mammals (pork, beef, lamb, veal, etc.), with a higher percentage of red muscle fiber than white (Abid et al., 2014). Meat which is preserved and flavoured using methods such as salting, smoking, fermentation and curing is commonly referred to as processed meat (Bouvard et al., 2015). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 7, 2018 Category: Cancer & Oncology Authors: S.M.K. Gamage, Lakal Dissabandara, Alfred King-Yin Lam, Vinod Gopalan Source Type: research

Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer
Cancer research continues to advance the outcome of patients with cancer as reflected by the higher survival rates and better quality of life. In an effort to enhance outcomes, researchers are focused on evaluating therapies with more effectiveness as well as lesser toxicities. Despite recent discoveries and advances in medicine, pancreatic cancer (PC) has a very poor prognosis that urgently requires novel therapeutic approaches. Currently, the five-year survival rate for PC is 8% (Siegel et al., 2017). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 7, 2018 Category: Cancer & Oncology Authors: Myrna Hurtado, Umesh T. Sankpal, Amalendu Ranjan, Rajasekhar Maram, Jamboor K. Vishwanatha, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Riyaz Basha Source Type: research

Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
Brain metastases (BM) are the most common intracranial neoplastic disease in adults, with an incidence of 9 –17% among all brain tumors (Nayak et al., 2012). They are usually caused by lung cancer (either non-small cell (NSCLC) and small cell (SCLC) histologies), breast cancer, melanoma and renal cell carcinoma, with a raising incidence related to the improvements in diagnostic and treatment approaches (Berghoff et al., 2014). However, prognosis remains poor, with a median overall survival (OS) ranging from 3 to 27 months (Brastianos et al., 2013), rendering BM still an unmet medical need. (Source: Critical Reviews i...
Source: Critical Reviews in Oncology Hematology - April 7, 2018 Category: Cancer & Oncology Authors: Michele Porcu, Cinzia Solinas, Paolo Garofalo, Evandro de Azambuja, Mario Scartozzi, Karen Willard-Gallo, Matthias Preusser, Luca Saba Source Type: research

The role of heme iron molecules derived from red and processed meat in the pathogenesis of colorectal carcinoma
Meat a versatile food, is a source of high quality proteins, essential amino acids and many micronutrients including iron, selenium, zinc, vitamin B6, vitamin B12 and omega-3- polyunsaturated fatty acids (Celada et al., 2016). Red meat is defined as flesh from mammals (pork, beef, lamb, veal, etc.), with a higher percentage of red muscle fiber than white (Abid et al., 2014). Meat which is preserved and flavoured using methods such as salting, smoking, fermentation and curing is commonly referred to as processed meat (Bouvard et al., 2015). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 7, 2018 Category: Cancer & Oncology Authors: S.M.K. Gamage, Lakal Dissabandara, Alfred King-Yin Lam, Vinod Gopalan Source Type: research

Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer
Cancer research continues to advance the outcome of patients with cancer as reflected by the higher survival rates and better quality of life. In an effort to enhance outcomes, researchers are focused on evaluating therapies with more effectiveness as well as lesser toxicities. Despite recent discoveries and advances in medicine, pancreatic cancer (PC) has a very poor prognosis that urgently requires novel therapeutic approaches. Currently, the five-year survival rate for PC is 8% (Siegel et al., 2017). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 7, 2018 Category: Cancer & Oncology Authors: Myrna Hurtado, Umesh T. Sankpal, Amalendu Ranjan, Rajasekhar Maram, Jamboor K. Vishwanatha, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Riyaz Basha Source Type: research